Evaluation of the Lu-concentration in in-house produced Lu-radiopharmaceuticals and commercially available Lutathera.

EJNMMI Radiopharm Chem

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Nuclear Medicine, Augustenburger Platz 1, Berlin, 13353, Germany.

Published: November 2023

AI Article Synopsis

  • Lu-radiopharmaceuticals can have different levels of the impurity [Lu]lutetium, which poses challenges for waste disposal and sterility testing due to its long half-life of 160.4 days.
  • An analysis of various Lu-samples confirmed that the Lu-concentration matched what was reported by suppliers and met European Pharmacopoeia standards.
  • However, compliance with national radioactivity regulations, especially in Germany, poses issues, as some samples could not be transported for sterility testing and waste water management must be monitored for Lu-concentration to ensure safety.

Article Abstract

Background: Lu-radiopharmaceuticals can contain the metastable impurity [Lu]lutetium with a physical half-life of 160.4 days, in varying concentrations depending on the route of production of the radionuclidic precursor [Lu]lutetium. Due to the long half-life of [Lu]lutetium, difficulties with waste disposal or sterility testing could arise. Here, we analyzed several Lu-samples of different origins and suppliers regarding their Lu-concentration.

Results: All samples tested showed a Lu-concentration in the range that was stated on the certificate of analysis from the supplier which is in accordance with the European Pharmacopoeia.

Conclusions: Although all Lu-concentrations were in accordance with the European Pharmacopoeia, we need to take into account the respective national legislation regarding radioactivity release limits. With regard to the German legislation, several probes for sterility testing in external laboratories could not be released for transport due to the concentration of [Lu]lutetium. Moreover, waste water tanks should specifically be monitored for Lu-concentration, when e.g. Lutathera is administered in the clinic.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628054PMC
http://dx.doi.org/10.1186/s41181-023-00222-2DOI Listing

Publication Analysis

Top Keywords

sterility testing
8
evaluation lu-concentration
4
lu-concentration in-house
4
in-house produced
4
produced lu-radiopharmaceuticals
4
lu-radiopharmaceuticals commercially
4
commercially lutathera
4
lutathera background
4
background lu-radiopharmaceuticals
4
lu-radiopharmaceuticals metastable
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!